Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4697494 | 1.00 | HRH3 (0.43) | HRH3EPHX2PARP10ACACBKDM4E | |
| SCHEMBL4698633 | 0.86 | HRH3 (0.44) | HRH3EPHX2PARP10ACACBKDM4E | |
| SCHEMBL14446164 | 0.82 | HRH3 (0.52) | HRH3 | |
| SCHEMBL14446160 | 0.82 | HRH3 (0.49) | HRH3 | |
| SCHEMBL14446158 | 0.81 | HRH3 (0.46) | HRH3 | |
| SCHEMBL14446226 | 0.80 | HRH3 (0.49) | HRH3 | |
| SCHEMBL14446177 | 0.80 | HRH3 (0.50) | HRH3 | |
| SCHEMBL14446171 | 0.80 | HRH3 (0.49) | HRH3 | |
| SCHEMBL4696955 | 0.79 | HRH3 (0.40) | HRH3EPHX2KDM4EALDH1A1PKM | |
| SCHEMBL4696956 | 0.79 | HRH3 (0.40) | HRH3EPHX2KDM4EALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1711473-B1 | SUBSTITUTED N-CYCLOHEXYLIMIDAZOLINONES HAVING AN MCH-MODULATORY EFFECT | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-01-09 | — | — | EP | disclosed |
| US-7241787-B2 | Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| EP-1711473-A1 | SUBSTITUTED N-CYCLOHEXYLIMIDAZOLINONES HAVING AN MCH-MODULATORY EFFECT | Sanofi-Aventis Deutschland GmbH (DE) | 2006-10-18 | — | — | EP | disclosed |
| US-20050176795-A1 | Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH | 2005-08-11 | — | — | US | disclosed |
| WO-2005070898-A1 | SUBSTITUTED N-CYCLOHEXYL IMIDAZOLINONES HAVING AN MCH-MODULATORY EFFECT | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176795-A1 | Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments | CYP11B1, CYP11B2, GPR119 | HRH3 3058/4885EPHX2 2278/4885PARP10 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.